Functional and therapeutic relevance of hepatocyte growth factor/c‐MET signaling in synovial sarcoma
Open Access
- 19 December 2016
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 107 (12) , 1867-1876
Abstract
Synovial sarcoma (SS) is an aggressive soft tissue sarcoma with a poor prognosis and, thus, novel therapeutic strategies for SS are urgently required. In the present study, we investigated the functional and therapeutic relevance of hepatocyte growth factor (HGF)/c‐MET signaling in SS. Both HGF and c‐MET were highly expressed in Yamato‐SS cells, resulting in activation of c‐MET and its downstream AKT and extracellular signal‐regulated kinase signaling pathways, whereas c‐MET was expressed but not activated in SYO‐1 or HS‐SY‐II cells. c‐MET‐activated Yamato‐SS cells showed higher anchorage‐independent growth ability and less sensitivity to chemotherapeutic agents than did c‐MET‐inactivated SYO‐1 or HS‐SY‐II cells. INC280, a selective c‐MET inhibitor, inhibited growth of Yamato‐SS cells both in vitro and in vivo but not that of SYO‐1 or HS‐SY‐II cells. INC280 induced cell cycle arrest and apoptosis, and blocked phosphorylation of c‐MET and its downstream effectors in Yamato‐SS cells. Co‐expression of HGF and c‐MET in SS clinical samples correlated with a poor prognosis in patients with SS. Taken together, activation of HGF/c‐MET signaling in an autocrine fashion leads to an aggressive phenotype in SS and targeting of this signaling exerts superior antitumor effects on c‐MET‐activated SS. HGF/c‐MET expression status is a potential biomarker for identification of SS patients with a worse prognosis who can benefit from c‐MET inhibitors.Keywords
Funding Information
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science (16H05448, 26462264)
This publication has 51 references indexed in Scilit:
- The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell SubtypeCancer Research, 2012
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastomaProceedings of the National Academy of Sciences, 2011
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3Clinical Cancer Research, 2011
- Modeling sarcomagenesis using multipotent mesenchymal stem cellsCell Research, 2011
- Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath TumorsClinical Cancer Research, 2011
- In vitromigration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factorsExperimental & Molecular Medicine, 2011
- Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell SarcomaCancer Research, 2010
- Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleosteminProceedings of the National Academy of Sciences, 2009
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007